Pipex Pharmaceuticals to Host Conference Call at 10:15am ET Wednesday July 9th to Discuss Phase II Clinical Trial Results in Dry Age-Related Macular Degeneration (AMD) With Oral Z-Monocys
           

<p>ANN ARBOR, MI--(Marketwire - July 8, 2008) -  Pipex Pharmaceuticals, Inc. (<exchange name="AMEX">AMEX</exchange>: <ticker name="PP">PP</ticker>), a
specialty pharmaceutical company developing innovative late-stage drug
candidates for the treatment of central nervous systems and autoimmune
diseases, today announced that it will hold a conference call on Wednesday,
July 9, 2008 at 10:15 a.m. ET to discuss the results of its double-blind,
placebo-controlled phase II clinical trial results in the treatment of dry
age-related macular degeneration (AMD) with oral Z-Monocys. Nicholas
Stergis, Vice Chairman and Chief Executive Officer of Pipex, will host the
call.

           

http://www.marketwire.com/mw/release.do?id=876843&sourceType=3